New eczema drug enters human testing phase

NCT ID NCT06248814

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety and effects of an experimental drug called BMS-986326 in adults with moderate-to-severe eczema. Researchers gave 64 participants either the drug or a placebo to check for side effects and measure how the drug behaves in the body. The main goal was to see if the treatment was safe and well-tolerated while also looking at early signs of whether it might help control eczema symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Rzeszów, Podkarpackie Voivodeship, 35-055, Poland
Local Institution - 0002

Córdoba, X, 14004, Spain
Local Institution - 0004

Prague, PR, 100 00, Czechia
Local Institution - 0005

Chemnitz, Saxony, 09117, Germany
Local Institution - 0006

Clermont-Ferrand, 63003, France
Local Institution - 0008

Pierre-Bénite, 69495, France
Local Institution - 0009

Pardubice, 530 02, Czechia
Local Institution - 0010

Nice, 06200, France
Local Institution - 0011

Berlin, State of Berlin, 10117, Germany
Local Institution - 0012

Lübeck, Schleswig-Holstein, 23562, Germany
Local Institution - 0013

Las Palmas de Gran Canaria, GC, 35010, Spain
Local Institution - 0015

Krakow, Lesser Poland Voivodeship, 30-149, Poland
Local Institution - 0016

Katowice, Silesian Voivodeship, 40-081, Poland

Conditions

Explore the condition pages connected to this study.

DERMATITIS, ATOPIC